Heart attack

Empagliflozin-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Empagliflozin(EMBA) (Brand name: Jardiance), a drug used in the treatment of TIIDM, increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene, 14/February/2018, 10.54 pm
Empagliflozin-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Empagliflozin(EMBA) (Brand name: Jardiance), a drug used in the treatment of TIIDM, increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene, 14/February/2018, 10.54 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was published, in the 6 April…

read more

Ribonucleic acid-based therapy for cardiac diseases: MDRL (Mitochondrial dynamic related lncRNA) decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy, via up-regulation of its target gene, 9/February/2019, 6.21 am
Ribonucleic acid-based therapy for cardiac diseases: MDRL (Mitochondrial dynamic related lncRNA) decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy, via up-regulation of its target gene, 9/February/2019, 6.21 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say   A study from the Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; and Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA shows that “Trbp regulates heart function through microRNA-mediated Sox6 repression.” This…

read more

Ribonucleic acid-based therapy for cardiomyocyte proliferation and heart regeneration: LncRNA PCGEM decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 6/February/2019, 11.00 pm
Ribonucleic acid-based therapy for cardiomyocyte proliferation and heart regeneration: LncRNA PCGEM decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 6/February/2019, 11.00 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; Key Laboratory of Molecular Target and…

read more

Molecular therapy for safeguarding your heart against cardiac dysfunction: Sofalcone, a gastrointestinal medication,  decreases tumor suppressor Mir-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 2/February/2019, 5.44 pm
Molecular therapy for safeguarding your heart against cardiac dysfunction: Sofalcone, a gastrointestinal medication,  decreases tumor suppressor Mir-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 2/February/2019, 5.44 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; Key Laboratory of Molecular Target and…

read more

Seladelpar (MBX8025/RWJ800025)-based therapy for Cardiac repair and myocardial infarction: Seladelpar (MBX8025/RWJ800025) increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up-regulation of its target gene, 31/January/2019, 11.14 pm
Seladelpar (MBX8025/RWJ800025)-based therapy for Cardiac repair and myocardial infarction: Seladelpar (MBX8025/RWJ800025) increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up-regulation of its target gene, 31/January/2019, 11.14 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel; Department of Biomedical Engineering, Duke University, Durham, North Carolina 27708,…

read more

Ribonucleic acid-based therapy for myocardial diseases: LncRNA NEAT1-based therapy for Cardiac repair and myocardial infarction: LncRNA  NEAT1 increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up-regulation of its target gene, 31/January/2018, 10.19 pm
Ribonucleic acid-based therapy for myocardial diseases: LncRNA NEAT1-based therapy for Cardiac repair and myocardial infarction: LncRNA  NEAT1 increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up-regulation of its target gene, 31/January/2018, 10.19 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel; Department of Biomedical Engineering, Duke University, Durham, North Carolina 27708,…

read more
Start Typing